Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw strong trading volume on Tuesday . 629,445 shares traded hands during trading, an increase of 170% from the previous session’s volume of 232,817 shares.The stock last traded at $17.71 and had previously closed at $17.79.

Wall Street Analysts Forecast Growth

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

Enliven Therapeutics Stock Performance

The company has a market cap of $814.03 million, a P/E ratio of -8.12 and a beta of 1.06. The firm’s 50-day simple moving average is $17.14 and its 200 day simple moving average is $14.53.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Insider Activity

In related news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total transaction of $7,500,000.00. Following the transaction, the insider now owns 771,983 shares of the company’s stock, valued at approximately $11,579,745. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the sale, the insider now owns 771,983 shares in the company, valued at approximately $11,579,745. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $16.89, for a total value of $202,680.00. The disclosure for this sale can be found here. Insiders sold a total of 742,266 shares of company stock valued at $12,891,980 in the last ninety days. 45.80% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

A number of large investors have recently bought and sold shares of ELVN. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics in the third quarter valued at approximately $157,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth about $66,000. Exchange Traded Concepts LLC grew its holdings in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares in the last quarter. AJOVista LLC acquired a new stake in Enliven Therapeutics in the 4th quarter valued at approximately $28,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after acquiring an additional 1,029 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.